CMMB Q4 2021 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$11,050

Operating Income

-$5M

Net Income

-$5M

EPS (Diluted)

$-1.77

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$64M

Total Liabilities

$3M

Stockholders' Equity

$61M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$11,050	$0	—
Operating Income	-$5M	-$2M	-158.7%
Net Income	-$5M	-$2M	-158.1%